Innostellar Biotherapeutics Co.,Ltd
Innostellar Biotherapeutics Co.,Ltd
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) | wet macular degeneration | Recruiting | Phase 3 | 2026-08-06 | NCT07317934 | |
| Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | Diabetic Macular Edema (DME) | Recruiting | Early phase 1 | 2026-03-10 | NCT07362927 | |
| A Study of LX107 Gene Therapy in AIPL1-IRD Patients | eye disorder, inherited retinal dystrophy, retinal degeneration, retinal disorder | Recruiting | Early phase 1 | 2026-03-10 | NCT07063030 | |
| Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | Neovascular Age-related Macular Degeneration | Recruiting | Early phase 1 | 2026-03-10 | NCT07053358 | |
| Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-03-06 | NCT06196840 | |
| Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, not recruiting | Phase 1 | 2026-03-06 | NCT06196827 | |
| Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, not recruiting | Phase 3 | 2026-03-05 | NCT07054632 | |
| LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 | 2025-07-01 | NCT06198413 | |
| Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy | inherited retinal dystrophy | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-29 | NCT06212297 |